Wells Fargo maintains Gilead Sciences at Overweight, raises price target to $190 from $165
Wells Fargo raised its price target for Gilead Sciences to $190 from $165, implying a 14.7% upside from the last close. The firm maintained an Overweight rating. Recent analyst targets range from $131 to $200.
How this was made
The 30-second read
Why it matters
The higher target may prompt short covering and new buying, modestly boosting the stock.
Market read
A fresh analyst upgrade provides a short‑term catalyst for GILD, though broader market impact is limited.
What to watch
Potential regulatory or clinical trial risks not reflected in the new target.
Background
Wells Fargo's analyst note updates Gilead's valuation based on recent pipeline and market conditions.
Ticker impact
Wells Fargo raised its price target on Gilead Sciences to $190 from $165, indicating a fresh bullish analyst view.
likely modest upward pressure as investors price in the higher target
The 15% target increase signals improved expectations, which can attract buying interest.
Market effects
May lift sentiment in the biotech sector as peers see analyst optimism.
Limited to US markets where GILD trades.
Minimal global impact beyond biotech investors.
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- analystWells Fargo
Equity research firm issuing the target raise.
- companyGilead Sciences
Biopharma company receiving the upgraded target.
